ES2151927T3 - Interleuquina-15. - Google Patents

Interleuquina-15.

Info

Publication number
ES2151927T3
ES2151927T3 ES94915781T ES94915781T ES2151927T3 ES 2151927 T3 ES2151927 T3 ES 2151927T3 ES 94915781 T ES94915781 T ES 94915781T ES 94915781 T ES94915781 T ES 94915781T ES 2151927 T3 ES2151927 T3 ES 2151927T3
Authority
ES
Spain
Prior art keywords
polypeptides
derivatives
mammalian
interleuquina
etf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915781T
Other languages
English (en)
Inventor
Kenneth H Grabstein
Dirk M Anderson
June R Eisenman
Charles Rauch
Victor Fung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Priority claimed from ZA942636A external-priority patent/ZA942636B/xx
Application granted granted Critical
Publication of ES2151927T3 publication Critical patent/ES2151927T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE DISPONE UN POLIPEPTIDO DE FACTOR DE CELULAS T DERIVADAS DE EPITELIO DE MAMIFERO ("ETF") A LA QUE AQUI SE LLAMA INTERLEUCINA15 ("IL-15"), DERIVADOS DEL MISMO, SECUENCIAS DE ADN, MOLECULAS DE ADN RECOMBINANTE Y CELULAS HUESPED TRANSFORMADAS QUE PRODUCEN POLIPEPTIDOS DE IL-15. EN CONCRETO, ESTA INVENCION PROPORCIONA POLIPEPTIDOS AISLADOS DE IL-15 DE MAMIFERO Y DERIVADOS DE LOS MISMOS QUE REGULAN SUCESOS EN LA PROLIFERACION DE LINFOCITOS T.
ES94915781T 1994-04-06 1994-04-06 Interleuquina-15. Expired - Lifetime ES2151927T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NZ266264A NZ266264A (en) 1994-04-06 1994-04-06 Mammalian epithelium-derived t-cell factor called interleukin-15
PCT/US1994/003793 WO1995027722A1 (en) 1994-04-06 1994-04-06 Interleukin-15
ZA942636A ZA942636B (en) 1994-04-06 1994-04-18 Interleukin-15
OA60897A OA10375A (en) 1994-04-06 1996-09-27 Interleukin-15

Publications (1)

Publication Number Publication Date
ES2151927T3 true ES2151927T3 (es) 2001-01-16

Family

ID=33314371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915781T Expired - Lifetime ES2151927T3 (es) 1994-04-06 1994-04-06 Interleuquina-15.

Country Status (11)

Country Link
EP (1) EP0772624B1 (es)
AT (1) ATE196315T1 (es)
CA (1) CA2186747C (es)
DE (1) DE69425906T2 (es)
DK (1) DK0772624T3 (es)
ES (1) ES2151927T3 (es)
GR (1) GR3035019T3 (es)
NZ (1) NZ266264A (es)
OA (1) OA10375A (es)
PT (1) PT772624E (es)
WO (1) WO1995027722A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU700250B2 (en) * 1995-04-02 1998-12-24 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for curing thrombocytopenia
WO1997014433A1 (en) 1995-10-17 1997-04-24 Wayne State University Chicken interleukin-15 and uses thereof
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
CA2252557A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
DK0927254T3 (da) * 1996-04-26 2005-10-03 Beth Israel Hospital Interleukin-15-antagonister
US6087172A (en) * 1997-10-31 2000-07-11 Hisamitsu Pharmaceutical Co., Inc. Ribozymes targeted to human IL-15 mRNA
US5985663A (en) * 1998-11-25 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of interleukin-15 expression
AU3373300A (en) * 1999-02-24 2000-09-14 Wistar Institute Of Anatomy And Biology, The Method of modifying cytotoxic cells and uses thereof
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US6797263B2 (en) 2000-05-12 2004-09-28 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CU23093A1 (es) * 2002-10-09 2005-10-19 Ct Ingenieria Genetica Biotech Composición vacunal que comprende interleucina-15 (il-15)
CN100427597C (zh) * 2003-11-26 2008-10-22 中国医学科学院基础医学研究所 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法
CU23472A1 (es) 2004-09-17 2009-12-17 Ct Ingenieria Genetica Biotech Péptido antagonista de la interleucina-15
EP1809321B1 (en) * 2004-10-08 2012-03-14 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Adoptive immunotherapy with enhanced t lymphocyte survival
MX2007014474A (es) 2005-05-17 2008-02-07 Univ Connecticut Composiciones y metodos para inmunomodulacion en un organismo.
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
NZ569541A (en) 2006-01-13 2012-05-25 Us Gov Health & Human Serv Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
CN108948177B (zh) 2007-05-11 2022-04-22 阿尔托生物科学有限公司 融合分子与il-15变异体
ES2466916T3 (es) 2007-06-27 2014-06-11 Admune Therapeutics Llc Complejos de IL-15 e IL-15R alfa y usos de los mismos
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
AU2010282280B2 (en) 2009-08-14 2016-06-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 to increase thymic output and to treat lymphopenia
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
ES2651170T3 (es) 2010-09-21 2018-01-24 Altor Bioscience Corporation Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
US10351824B2 (en) 2011-12-12 2019-07-16 Cell Medica Limited Process of expanding T cells
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
DK2986312T3 (da) 2013-04-19 2022-02-14 Cytune Pharma Cytokinafledt behandling med reduceret vaskulært lækagesyndrom
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
MX2017000116A (es) 2014-06-30 2017-05-30 Altor Bioscience Corp Moleculas basadas en il-15 y metodos para su uso.
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
WO2017218533A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
AU2017345791B2 (en) 2016-10-21 2020-10-22 Altor Bioscience Corporation Multimeric IL-15-based molecules
CA3059634A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
KR102008429B1 (ko) 2017-06-30 2019-08-07 아주대학교산학협력단 인터루킨-15/인터루킨-15 수용체 알파-Fc 복합체를 포함하는 염증질환 치료 또는 예방용 조성물
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
US20220195396A1 (en) * 2020-12-03 2022-06-23 Century Therapeutics, Inc. Genetically Engineered Cells and Uses Thereof
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Also Published As

Publication number Publication date
EP0772624B1 (en) 2000-09-13
ATE196315T1 (de) 2000-09-15
EP0772624A1 (en) 1997-05-14
GR3035019T3 (en) 2001-03-30
OA10375A (en) 2001-11-16
CA2186747A1 (en) 1995-10-19
WO1995027722A1 (en) 1995-10-19
NZ266264A (en) 1997-01-29
PT772624E (pt) 2001-03-30
DK0772624T3 (da) 2000-11-13
EP0772624A4 (en) 1997-07-02
DE69425906D1 (en) 2000-10-19
CA2186747C (en) 2009-01-27
DE69425906T2 (de) 2001-03-29

Similar Documents

Publication Publication Date Title
DE69425906T2 (de) Interleukin-15
NO975437D0 (no) Nytt CD40L-mutein
ATE184052T1 (de) Gdf-1 und uog1 proteine
ATE252113T1 (de) Verwendung von wnt polypeptiden
DE69535147D1 (de) Überexpression von säugetier- und virusproteinen
ATE389666T1 (de) Hohe expressionsrate von proteinen
MX9503362A (es) Nuevos anticuerpos br96 mutantes y equivalentes funcionales que reaccionan con carcinomas humanos.
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
MX9708426A (es) Polipeptido hk2 de variante estable.
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
EP0785716A4 (en) CYTOKINE CALLED LERK-6
AU656353B2 (en) New variants derived from interferons of type I, production process thereof and their applications
SE9401380D0 (sv) Ny celltillväxt-relaterad peptid och användning därav
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
NO974713D0 (no) Gener som koder for lymfocyttinterferon-regulatorisk faktor (LSIRF) polypeptider
AU7378087A (en) Interleukin-2 induced antineoplastic peptide
WO1997025421A3 (en) PROTEIN INDUCED BY DEPRENYL$m(3)
ITMI931034A1 (it) Processo per la preparazione di proteine inibenti i ribosomi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 772624

Country of ref document: ES